gip glp 1 agonist tirzepatide Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes GLP1-GIP receptor co-agonists: a promising
Description
Exercise avoidance behaviour is a sensitive indicator of substance-induced malaise in mice 35
The three glucose-lowering medications are common second-line therapies recommended by the guidelines [8, 9]
Therefore, if a new oral drug in development is intended to be co-administered with a GLP-1 agonist, we highly recommend conducting a healthy volunteer drug-drug interaction prior to Phase 3 trials to characterize the impact on the PK of the candidate new drug
2010;340(mar12 1):b5087b5087
10.1056/NEJMoa2028395 96 NietoL
